Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-04-05
2011-04-05
Bristol, Lynn (Department: 1643)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07919467
ABSTRACT:
The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as ovarian carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against cancer.
REFERENCES:
patent: 4235871 (1980-11-01), Papahadjopoulos et al.
patent: 4501728 (1985-02-01), Geho et al.
patent: 4690915 (1987-09-01), Rosenberg
patent: 4722848 (1988-02-01), Paolette et al.
patent: 4837028 (1989-06-01), Allen
patent: 4844893 (1989-07-01), Honski et al.
patent: 5019369 (1991-05-01), Presant et al.
patent: 5635363 (1997-06-01), Altman et al.
patent: 5645994 (1997-07-01), Huang et al.
patent: 5747269 (1998-05-01), Rammensee et al.
patent: 5763219 (1998-06-01), Keyomarsi
patent: 5972643 (1999-10-01), Lobanenkov
patent: 6140464 (2000-10-01), Pfreundschuh et al.
patent: 6168804 (2001-01-01), Samuel et al.
patent: 6548064 (2003-04-01), Tureci et al.
patent: 6867283 (2005-03-01), Barnea
patent: 7083789 (2006-08-01), Ramakrishna et al.
patent: 7087712 (2006-08-01), Brossart et al.
patent: 7270819 (2007-09-01), Tureci et al.
patent: 2004/0236091 (2004-11-01), Chicz et al.
patent: 93/10814 (1993-06-01), None
patent: WO 02/46416 (2002-06-01), None
patent: WO 2007/081680 (2007-07-01), None
Smith et al. (Nature Biotechnology 15:1222-1223 (1997)).
Brenner (Trends in Genetics 15:132-133 (1999)).
Voskoglou-Nomikos (Clin. Can. Res. 9:4227-4239 (2003)).
Dennis (Nature 442:739-741 (2006)).
Cespdes et al. (Clin. Transl. Oncol. 8(5):318-329 (2006)).
Talmadge et al. (Am. J. Pathol 170(3):793-804 (2007)).
clinicaltrials.gov search (ImmunoVaccine Technologies, Inc., pp. 1-3; Jan. 29, 2011).
Adachi et al., 1992, Nucleic Acids Research, vol. 20, pp. 5297-5303.
Boon, T. et al., Ann. Rev. Immunol., 12:337-365 (1994).
Celluzzi, C. M. et al., J. Exp. Med., 183:283-287 (1996).
European Search Report, dated Jan. 26, 2005.
Gilboa, E., Immunity, 11:263-270 (1999).
Gluzman, Cell, 23:175 (1981).
Harding, C. H. III, Eur. J. Immunol. 22:1865-1869 (1992).
Henderson R. A. et al, Direct Identification of an Endogenous Peptide Reognized by Multiple HLA-A2.1 Specific Cytotoxic T Cells, National Academy of Sciences, vol. 90, pp. 10275-10279 (Nov. 1993).
Hogan, K. T. et al., The peptide Recognized by HLAA68.2-Restricted, Squamous Cell Carcinoma of the Lung-Specific Cytotoxic T Lymphocytes is Derviced froma Mutated Elongation Factor 2 Gene, American Association for Cancer Research, vol. 58, No. 22, pp. 5144-5150 (Nov. 15, 1998).
Hunt, D. F. et al., Proc. Natl. Acad. Sci. USA, 83:6233-6237 (1986).
Hunt, D. F. et al., Science, 255:1261-1263 (1992).
Jacob, L. et al., Int. J. Cancer, 71:325-332 (1997).
Joslyn G. et al., Identification of Deletion Mutations and Three New Genes at the Familial Polyposis Locus, Cell, vol. 66, No. 3, pp. 604-614 (1991).
Kabat et al., J. Biol. Chem., 252:6609-6616 (1977).
Kinzler, K. W. et al., Identification of FAP Locus Genes from Chromosome 5Q21, Science, vol. 253, No. 5020, pp. 661-665 (1991).
Lauritzsen et al (International Journal of Cancer, 1998, vol. 78, pp. 216-222.
Ljunggren, H. G. et al., Nature, 346:476-480 (1990).
Loannides, C. G. et al., J. Immunol., 146:1700-1707 (1991).
Mayordome, J. et al., Nat. Med., 1:1297-1302 (1995).
Moore, J. W. et al., Cell, 54:777-785 (1988).
North, R. J. et al., Infect. Immun., 67:2010-2012 (1999).
Parkhurst, M. R. et al., J. Immunol., 157:2539-2548 (1996).
Peiper, M. et al., Eur. J. Immunol., 27:1115-1123 (1997).
Peoples, G.E. et al., Surgery, 114:227-234 (1993).
Perez-Diez, A. et al., Cancer Res., 58:5305-5309 (1998).
Plebanski et al., Eur. J. Immunol., 25:1783 (1995).
Posneft, D. N. et al., J. Biol. Chem., 263:1719-1725 (1988).
Reddy, R. et al., J. Immunol Methods, 141:157-163 (1991).
Riddell, S. R. et al., J. Immunol. Methods, 128:189-201 (1990).
Riddell, S. R. et al., Science, 257:238-241 (1992).
Rock, K. L. et al., Ann. Rev. Immunol., 17:739-779 (1999).
Rosenberg, S. A. et al., A New Era for Cancer Immunotherapy Based on the Genes that encode cancer antigens, Immunity, Cell Press, US, vol. 10, No. 3, pp. 281-287 (Mar. 1999).
Rosenberg, S. A. et al., N. Engl. J. Med., 319:1676-1680 (1988).
Rosenberg, S. A. et al., Nat. Med., 4:321-327 (1998).
Sarma et al., Journal of Experimental Medicine, 1999, vol. 189, pp. 811-820.
Schendel, D. J. et al., J. Immunol., 151:4209-4220 (1993).
Sherman, LA et al., 1998, Critical Reviews in Immunol., 18(1-2): 47-54.
Slingluff, C. L. Jr. et al., Cancer Res., 54:2731-2737 (1994).
Slingluff, C. L. Jr. et al., J. Immunol., 150:2955-2963 (1993).
Slovin, S.F. et al., J. Immunol., 137:3042-3048 (1987).
Tsai-Pflugfelder et al., Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22, Proc. Natl. Acad. Sci. USA, vol. 85, pp. 7177-7181 (1988).
Tuting, T. et al., J. Immunol., 160:1139-1147 (1998).
Voet et al., Biochemistry, John Wiley & Sons, 1990, pp. 60-63 only.
Walter, E. A. et al., N. Engl. J. Med., 333:1038-1044 (1995).
Watts, C., Ann. Rev. Immunol., 15:821-850 (1997).
Wolfel, T. et al., Int. J. Cancer, 54:636-644 (1993).
Yasumura, S. et al., Cancer Res., 53:1461-1468 (1993).
Yewdell, J. W. et al., Ann. Rev. Immunol., 17:51-88 (1999).
Yoshino, I. et al., cancer Res., 54:3387-3390 (1994).
Zeh, H. J. III et al., Hum. Immunol., 39:79-86 (1994).
Zitvogel, L. et al., J. Exp. Med., 183:87-97 (1996).
Hengstler et al. (1999) Cancer Research 59, 3206-3214.
Imal et al. (1995) Clinical Cancer Research 1, 417-424.
Mosolits et al. (1999) Cancer Immunol. Immunother. 47, 315-320 (first page only).
Fisk Bryan et al., “Identification of naturally processed human ovarian peptides recognized by tumor-associated CD8+ cytotoxic T lymphocytes”—Cancer Research, vol. 57, No. 1, 1997, pp. 87-93.
Fisk B et al., “Identification of an Immunodominant Peptide of HER-2
eu Protooncogene Recognized by Ovarian Tumor-specific Cytotoxic T Lymphocyte Lines”—The Journal of Experimental Medicine, Rockefeller University Press, United States, vol. 181, No. 6, Jun. 1, 1995, pp. 2109-2117.
Huynh Khanh D et al., “BCor, a novel corepressor involved in BCL-6 repression”—Genes and Development, vol. 14, No. 14, Jul. 15, 2000, pp. 1810-1823.
Ramakrishna V et al., “Generation and Phenotypic Characterization of New Human Ovarian Cancer Cell Lines With the Identification of Antigens Potetially Recognizable by HLA-Restricted Cytotoxic T Cells”—Journal of Cancer, John Wiley & Sons, Inc., United States, Switzerland, Germany vol. 73, No. 1, Sep. 26, 1997, pp. 143-150.
EPO 019995455.1—Office Action (Feb. 29, 2008).
EPO 019995455.1—Result of Consultation (Aug. 13, 2009).
EPO 019995455.1—Minutes of Oral Proceedings (Oct. 11, 2010).
EPO 019995455.1—Decision to Refuse a European Patent Application (Nov. 10, 2010).
Arceci, Journal of Molecular Medicine, 76, 1998.
Benjamini et al (edited by); Immunology: A Short Course, p. 40, 1991.
Bodey et al; Anticancer Research, 20, 2000.
Boon, Advances in Cancer Research, 58, 1992.
Cox et al, Science, 264, 1994.
Deppenmeier et al (SwissProt, Accession No. Q8PWE3, version 1, p. 1, available Oct. 1, 2002).
Elgert et al., Immunology: Understanding the Immune System, 1996.
Lollini et al. Curr. Cancer Drug Targets 5(3), 2005.
Lollini et al., Trends Immunol, 24(2); (2003).
National Cancer Institute (Cancer Facts, Fact Sheet 5, 1998.
Rongcun, Y et al., Journal of Immunology, 163, 1999.
Wang, et al., Exp. Opin. Biol. Ther., 1(2), 2001.
Watson et al. (edited by), Molecular Biology of the Gene, p. 43 (1988).
Zhou et al., J. Exp. Med., 183:87-97 (1996).
PCT/US2001/047290 ISR (Date of Report—Sep. 14, 2005).
PCT/US2007/077250 ISR (Date of Report—Aug. 21, 2008).
PCT/US2007/024787 ISR (Date of Report—Sep. 18, 2008).
EPO 10178439.5—Search Report (Feb. 3, 2011).
Schirle, Markus, et al.; Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach; European Journal of Immunology, Aug. 1, 2000, vol. 30, No. 8, pp
Keller Lorraine H.
Philip Ramila
Ramakrishna Venky
Ross Mark M.
Ballard Spahr LLP
Bristol Lynn
Immunotope, Inc.
LandOfFree
Cytotoxic T-lymphocyte-inducing immunogens for prevention,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cytotoxic T-lymphocyte-inducing immunogens for prevention,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytotoxic T-lymphocyte-inducing immunogens for prevention,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2641249